21157403

Source:http://linkedlifedata.com/resource/pubmed/id/21157403

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0022671, umls-concept:C0026933, umls-concept:C0031327, umls-concept:C0085149, umls-concept:C0205195, umls-concept:C0376387, umls-concept:C1515568, umls-concept:C2742796
pubmed:issue	3
pubmed:dateCreated	2011-1-28
pubmed:abstractText	Sotrastaurin is a protein kinase C inhibitor in the development for prevention of organ rejection after renal transplantation.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0132144
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents, http://linkedlifedata.com/resource/pubmed/chemical/Mycophenolic Acid, http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles, http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines, http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus, http://linkedlifedata.com/resource/pubmed/chemical/sotrastaurin
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	1534-6080
pubmed:author	pubmed-author:ArnsWolfgangW, pubmed-author:BuddeKlemensK, pubmed-author:DantalJacquesJ, pubmed-author:GrinyoJosep MJM, pubmed-author:KovarikJohn MJM, pubmed-author:ProotPieterP, pubmed-author:RostaingLionelL, pubmed-author:Sotrastaurin Renal Transplant Study Group, pubmed-author:SteigerJürg UJU
pubmed:issnType	Electronic
pubmed:day	15
pubmed:volume	91
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	317-22
pubmed:meshHeading	pubmed-meshheading:21157403-Adolescent, pubmed-meshheading:21157403-Adult, pubmed-meshheading:21157403-Aged, pubmed-meshheading:21157403-Dose-Response Relationship, Drug, pubmed-meshheading:21157403-Drug Therapy, Combination, pubmed-meshheading:21157403-Enzyme Inhibitors, pubmed-meshheading:21157403-Female, pubmed-meshheading:21157403-Follow-Up Studies, pubmed-meshheading:21157403-Graft Rejection, pubmed-meshheading:21157403-Humans, pubmed-meshheading:21157403-Immunosuppressive Agents, pubmed-meshheading:21157403-Kidney Transplantation, pubmed-meshheading:21157403-Longitudinal Studies, pubmed-meshheading:21157403-Male, pubmed-meshheading:21157403-Middle Aged, pubmed-meshheading:21157403-Mycophenolic Acid, pubmed-meshheading:21157403-Prospective Studies, pubmed-meshheading:21157403-Pyrroles, pubmed-meshheading:21157403-Quinazolines, pubmed-meshheading:21157403-Tacrolimus, pubmed-meshheading:21157403-Treatment Outcome, pubmed-meshheading:21157403-Young Adult
pubmed:year	2011
pubmed:articleTitle	Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients.
pubmed:affiliation	Clinical Pharmacology and Clinical Research, Novartis Pharmaceuticals, Basel, Switzerland. john.kovarik@novartis.com
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II